You are here

REAL-TIME FMRI TECHNOLOGY ENABLING A NOVEL TREATMENT MODALITY IN DEPRESSION

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44MH088007-02
Agency Tracking Number: R44MH088007
Amount: $1,493,463.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIMH
Solicitation Number: PA08-001
Timeline
Solicitation Year: 2011
Award Year: 2011
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
99 EL CAMINO REAL
MENLO PARK, CA -
United States
DUNS: 145376724
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CHRISTOPHER DECHARMS
 (650) 585-5303
 cdecharms@omneuron.com
Business Contact
 JON HAWKINSON
Phone: (650) 585-5313
Email: jhawkinson@omneuron.com
Research Institution
 Stub
Abstract

This research program develops novel tools and methods for high-throughput, real-time analysis of brain activation data, harnessing the power of real-time fMRI (rtfMRI) analysis to allow novel types of cognitive interventions in the investigation and treatment of depression. Our group has demonstrated that rtfMRI-based training enables subjects to learn control over activation of anatomically-localized brain regions, leading to reductions in disease symptoms, including pain and depressive symptoms. These investigations further the NIH mission by advancing understanding of distributed brain mechanisms of depression and by definitively testing a novel therapeutic modality for alleviating a condition which is responsible for substantial human suffering and healthcare cost. This research program will develop novel high-throughput analysis tools that directly enable new methods for cognitive interventions based on rtfMRI-based training. This research will conduct a randomized, controlled, clinical trial of this novel investigative therapeutic technology and methods for treating depression in patients refractory to prior treatment modalities. Decreasing depressive symptoms, and improving control over mood are the initial clinical targets. Phase I: 1) Demonstratefeasibility and efficacy of tasks for cognitive control over mood in depressive patients; 2) Identify brain regions with activations associated with cognitive control over mood in depressive patients. Phase II: 1) Conduct a double-blind, sham-controlled clinical trial of long-term repetitive rtfMRI-based training in depressive patients, 2) Demonstrate enhanced modulation of brain region activation in depressive patients using rtfMRI, and 3) Demonstrate decreased depressive symptoms and increased control over mood following rtfMRI training.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government